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Abstract
IMPORTANCE—Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative 
disorder characterized by loss of upper and lower motor neurons. Although novel ALS genetic 
variants have been identified, the shared genetic risk between ALS and other neurodegenerative 
disorders remains poorly understood.
OBJECTIVES—To examine whether there are common genetic variants that determine the risk 
for ALS and other neurodegenerative diseases and to identify their functional pathways.
DESIGN, SETTING, AND PARTICIPANTS—In this study conducted from December 1, 2016, 
to August 1, 2017, the genetic overlap between ALS, sporadic frontotemporal dementia (FTD), 
FTD with TDP-43 inclusions, Parkinson disease (PD), Alzheimer disease (AD), corticobasal 
degeneration (CBD), and progressive supranuclear palsy (PSP) were systematically investigated in 
124 876 cases and controls. No participants were excluded from this study. Diagnoses were 
established using consensus criteria.
MAIN OUTCOMES AND MEASURES—The primary outcomes were a list of novel loci and 
their functional pathways in ALS, FTD, PSP, and ALS mouse models.
RESULTS—Among 124 876 cases and controls, genome-wide conjunction analyses of ALS, 
FTD, PD, AD, CBD, and PSP revealed significant genetic overlap between ALS and FTD at 
known ALS loci: rs13302855 and rs3849942 (nearest gene, C9orf72; P = .03 for rs13302855 and 
P = .005 for rs3849942) and rs4239633 (nearest gene, UNC13A; P = .03). Significant genetic 
overlap was also found between ALS and PSP at rs7224296, which tags the MAPT H1 haplotype 
(nearest gene, NSF; P = .045). Shared risk genes were enriched for pathways involving neuronal 
function and development. At a conditional FDR P < .05, 22 novel ALS polymorphisms were 
found, including rs538622 (nearest gene, ERGIC1; P = .03 for ALS and FTD), which modifies 
BNIP1 expression in human brains (35 of 137 females; mean age, 59 years; P = .001). BNIP1 
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expression was significantly reduced in spinal cord motor neurons from patients with ALS (4 
controls: mean age, 60.5 years, mean [SE] value, 3984 [760.8] arbitrary units [AU]; 7 patients with 
ALS: mean age, 56 years, mean [SE] value, 1999 [274.1] AU; P = .02), in an ALS mouse model 
(mean [SE] value, 13.75 [0.09] AU for 2 SOD1 WT mice and 11.45 [0.03] AU for 2 SOD1 G93A 
mice; P = .002) and in brains of patients with PSP (80 controls: 39 females; mean age, 82 years, 
mean [SE] value, 6.8 [0.2] AU; 84 patients with PSP: 33 females, mean age 74 years, mean [SE] 
value, 6.8 [0.1] AU; β = −0.19; P = .009) or FTD (11 controls: 4 females; mean age, 67 years; 
mean [SE] value, 6.74 [0.05] AU; 17 patients with FTD: 10 females; mean age, 69 years; mean 
[SE] value, 6.53 [0.04] AU; P = .005).
CONCLUSIONS AND RELEVANCE—This study found novel genetic overlap between ALS 
and diseases of the FTD spectrum, that the MAPT H1 haplotype confers risk for ALS, and 
identified the mitophagy-associated, proapoptotic protein BNIP1 as an ALS risk gene. Together, 
these findings suggest that sporadic ALS may represent a selectively pleiotropic, polygenic 
disorder.
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are thought to 
represent a continuous disease spectrum.1 Clinically, ALS presents as progressive muscle 
wasting, hyperreflexia, and spasticity, whereas FTD is defined by cognitive and behavioral 
dysfunction. Between 40% and 50% of patients with ALS present with FTD-associated 
clinical phenotypes, including progressive aphasia, language impairment, and executive 
dysfunction.1 Neuropathologically, ALS is defined by the loss of upper and lower motor 
neurons and the formation of TDP-43, SOD1, and ubiquitin-positive inclusions within motor 
neurons. Frontotemporal dementia is defined by atrophy of the frontal and temporal lobes, 
and subtypes of FTD are distinguished by the types of inclusions in these regions (tau, FUS, 
TDP-43, and ubiquitin).2 Comparatively less is known about the shared pathobiology 
between ALS and other neurodegenerative diseases, such as Alzheimer disease (AD), 
corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), and Parkinson 
disease (PD).
Genetic factors offer insights into the molecular mechanisms underlying disease. Rare 
mutations in TDP43 (Gen-Bank 3435) are associated with ALS and FTD.3–5 Genetic studies 
have revealed expansions of the hexanucleotide repeat within the noncoding promoter region 
of C9orf72 (GenBank 203228) as the cause of ALS and FTD.6,7 However, beyond C9orf72 
and TDP43, the genetic overlap across sporadic forms of ALS, FTD, and other 
neurodegenerative diseases remains poorly understood.
One approach to assessing additional genetic risk among these diseases is to identify single-
nucleotide polymorphisms (SNPs) that are jointly associated with multiple traits.8–11 Using 
previously validated methods, we investigated the genetic overlap between ALS, FTD, PSP, 
CBD, AD, and PD. We then used molecular and bioinformatics approaches to begin to 
define the role that these shared risk genes play in neurodegeneration.
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Methods
Participant Samples
We evaluated summary statistics (P values and odds ratios) from genome-wide association 
studies (GWASs) for ALS, PD, AD, CBD, PSP, sporadic FTD, and autosomal dominant 
FTD with TDP-43 inclusions (eTable 1 in the Supplement). The GWASs were performed for 
individuals of European descent. Samples have been previously described in detail.12–18 The 
data set on ALS represents 31 independent cohorts of participants with ALS and control 
participants.14 Amyotrophic lateral sclerosis was diagnosed as probable or definite 
according to the 1994 El Escorial Criteria by neurologists specializing in motor neuron 
diseases.19 The data set on sporadic FTD included multiple subtypes within the FTD 
spectrum: behavioral variant FTD, semantic dementia, progressive nonfluent aphasia, and 
FTD overlapping with motor neuron disease. The relevant institutional review boards or 
ethics committees approved the research protocol of the individual GWASs used in the 
present analysis, and all human participants gave written informed consent. The Human 
Research Protection Program Institutional Review Board at University of California San 
Francisco waived consent for all participants. The Institutional Review Board determined 
that the use or disclosure of the information does not adversely affect the rights and welfare 
of the individuals and involves no more than a minimal risk to their privacy.
Statistical Analysis
Genetic Enrichment—We applied previously validated statistical methods to assess 
shared genetic risk and identify ALS susceptibility loci.9,10,20–22 We evaluated SNPs 
associated with increased risk for ALS and FTD, ALS and PD, ALS and AD, ALS and 
CBD, ALS and PSP, and ALS and FTD with TDP-43 inclusions. Using this approach, the 
genetic enrichment of phenotype A with phenotype B exists if the proportion of SNPs or 
genes associated with phenotype A increases as a function of the increased association with 
phenotype B. To evaluate enrichment, we constructed fold-enrichment and quantile-quantile 
plots of nominal −log10 P values for all ALS SNPs and for subsets of SNPs determined by 
the significance of their association with PD, AD, CBD, PSP, and FTD (sporadic FTD and 
FTD with TDP-43 inclusions)(eFigure 1 in the Supplement). Enrichment can be directly 
interpreted in terms of the true discovery rate, which is equal to 1 minus the false discovery 
rate (FDR) (eAppendix 1 in the Supplement).9,10,20–22 To minimize false positives, we used 
a 100-iteration random pruning with a linkage disequilibrium (LD) r2 < 0.2.21
Identification of Shared Risk Loci-Conjunction FDR—To identify specific loci 
jointly shared between ALS and PD, AD, CBD, PSP, or FTD (sporadic FTD and FTD with 
TDP-43 inclusions), we computed the conjunction FDR.8,9,20,21 The conjunction FDR is 
defined as the posterior probability that an SNP is null for either phenotype or for both 
simultaneously, given that the P values for both traits are as small, or smaller, than the P 
values for each trait individually (eAppendix 1 in the Supplement).8,9 We used an overall 
FDR threshold of P < .05 to indicate statistical significance. Manhattan plots were 
constructed based on the ranking of the conjunction FDR to illustrate the genomic location 
of the shared genetic risk loci.
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Identification of Novel Risk Loci-Conditional FDR—To identify specific ALS 
susceptibility loci as a function of genetic variants associated with the 6 neurodegenerative 
disorders, we computed conditional FDRs.20,21 The conditional FDR is an extension of the 
standard FDR, which incorporates information from GWAS summary statistics of a second 
phenotype to adjust its significance level. The conditional FDR is defined as the probability 
that an SNP is null in the first phenotype given that the P values in the first and second 
phenotypes are as small as or smaller than the observed ones. Ranking SNPs by the standard 
FDR or by P values gives the same ordering of SNPs. In contrast, if the primary and 
secondary phenotypes are related genetically, the conditional FDR reorders SNPs and results 
in a different ranking than that based on P values alone. We used an overall FDR threshold 
of P < .05 to indicate statistical significance, which means 5 expected false discoveries per 
100 reported. In addition, we constructed Manhattan plots based on the ranking of the 
conditional FDR to illustrate the genomic location. In all analyses, we controlled for the 
effects of genomic inflation by using intergenic SNPs (eAppendix 1 in the Supplement). 
Detailed information on the conditional FDR can be found in prior reports.20,21
Functional Evaluation of Shared Risk Loci—To determine whether the conjunction 
and conditional SNPs shared across ALS, PD, AD, CBD, PSP, and FTD (sporadic FTD and 
FTD with TDP-43 inclusions) modify gene expression, we evaluated cis-expression 
quantitative trait loci (eQTL) in a publicly available data set from neuropathologically 
confirmed control brains (UK Brain Expression Consortium, http://braineac.org/).23 To 
minimize multiple comparisons, we analyzed eQTL for the mean P value derived across the 
following brain regions: the cerebellum, frontal cortex, hippocampus, medulla, occipital 
cortex, putamen, substantia nigra, temporal cortex, thalamus, and white matter. To minimize 
false positives, we applied a Bonferroni-corrected P value of 1.5 × 10−3. To test for 
association between genotypes and gene expression, we used an analysis of covariance. We 
tested SNPs using an additive model in SAS (SAS Institute Inc). To evaluate cis-acting 
splicing quantitative trait loci (sQTL), we examined the associations of our shared risk SNPs 
with alternative splicing in control human brains.24 Each study reported genetic and 
expression data on brains from individuals of European descent.
Differential Expression of Shared Genetic Risk Variants in Tissues of Patients 
With ALS, PSP, FTD, AD, or PD—To determine whether shared risk genes identified by 
the conjunction FDR, the conditional FDR, and genes in cis-eQTL were differentially 
expressed in tissue from patients with ALS compared with controls, we analyzed the gene 
expression of the target genes in motor neurons isolated from 11 patients with ALS and 
controls (Gene Expression Omnibus [GEO] accession number GSE833).25 To validate the 
genes identified in GSE833, we examined expression data from a well-characterized mouse 
model.26 The RNA expression data were analyzed in nontransgenic SOD1 WT and SOD1 
G93A mice at 75 and 110 days (GEO accession number GSE4390).27 SOD1 G93A mice are 
presymptomatic at 75 days and exhibit hindlimb paralysis at 110 days.26,27
To determine whether differentially expressed genes in ALS were altered across brains with 
neurodegenerative disease, we analyzed the gene expression of the target genes using 
publicly available data sets. Differential gene expression was analyzed from the following 
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data sets: the temporal cortices from patients with PSP and control brains (Synapse ID No. 
syn6090802)28 and the frontal, hippocampus, and cerebellum from patients with FTD and 
controls (GEO accession number E13162).29 Each data set of control and disease tissue was 
obtained from individuals of European descent. All analyses were performed using analysis 
of covariance in SAS.
Gene Ontologic Features and Network-Based Functional Association 
Analyses—To identify enrichments in gene ontologic features associated with the ALS, 
PD, AD, CBD, PSP, and FTD (sporadic FTD and FTD with TDP-43 inclusions) shared risk 
genes identified by the conjunction FDR, the conditional FDR, and genes in cis-eQTL, we 
used the Consensus Path Database, which compares gene ontologic terms between 
background and candidate gene sets using the hypergeometric test and generates P values 
that are corrected for multiple testing using the FDR. Gene ontologic analyses were 
performed using the Consensus Path Database (Release 31; http://cpdb.molgen.mpg.de/).
30,31
 We used the default background gene set, which includes 18 043 genes. Biological, 
cellular, and molecular gene ontologic terms were included in a single analysis.
Results
Selective Shared Genetic Risk Between ALS, PD, AD, CBD, PSP, and FTD
We identified enrichment in ALS SNPs across different levels of significance with FTD, 
PSP, and CBD (Figure 1). Applying progressively stringent P value thresholds for ALS 
SNPs (ie, increasing values of nominal −log10 P value), we found up to 300-fold enrichment 
using FTD with TDP-43 inclusions, 150-fold enrichment using FTD, 75-fold enrichment 
using PSP, and 25-fold enrichment using CBD (Figure 1). In contrast, we found minimal or 
no enrichment in ALS SNPs as a function of AD or PD (Figure 1).
At a conjunction FDR P < .05, we identified 5 SNPs that were jointly associated with 
increased risk for ALS and FTD with TDP-43 inclusions, ALS and FTD, or ALS and PSP 
(Figure 1 and Table 1). These SNPs included the following: (1) rs9820623 (nearest gene, 
MOBP [GenBank 17433]; FDR ALS and PSP, P = 4.99 × 10−3); (2) rs13302855 (nearest 
gene, C9orf72; FDR ALS and FTD, P = 3.13 × 10−2); (3) rs3849942 (nearest gene, C9orf72; 
FDR ALS and FTD with TDP-43 inclusions, P = 4.88 × 10−3); (4) rs7224296 (nearest gene, 
NSF [GenBank 4905]; FDR ALS and PSP, P = 4.52 × 10−2);(5) rs4239633 (nearest gene, 
UNC13A [GenBank 23025]; FDR ALS and FTD, P = 3.05 × 10−2).
Conditional FDR Analysis and Novel Risk Loci
Conditional FDR analysis revealed 29 additional risk loci at an FDR P < .05 (eFigure 1 and 
eTable 2 in the Supplement). Signals at rs3849943, rs10511816, and rs13302855 (nearest 
gene, C9orf72; rs3849943: FDR for ALS and FTD, P = 5.30 × 10−9, ALS P = 4.56 × 10−19; 
rs10511816: FDR for ALS and FTD, P = 4.97 × 10−9, ALS P = 6.08 × 10−11; rs13302855: 
FDR for ALS and FTD, P = 2.03 × 10−4; ALS P = 4.04 × 10−6); rs12608932 (nearest gene, 
UNC13A; FDR for ALS and FTD, P = 1.04 × 10−6; ALS P = 1.83 × 10−8); rs1768208 and 
rs13079368 (nearest gene, MOBP; rs1768208: FDR for ALS, FTD, and PSP, P = 6.89 × 
10−3, ALS P = 4.04 × 10−5; rs13079368: FDR for ALS, FTD, and PSP, P = 1.99 × 10−3; 
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ALS P = 4.11 × 10−5); and rs7813314 (nearest gene, BC045738 [GenBank 101927815]; 
FDR for ALS and FTD, P = 4.86 × 10−3; ALSP = 7.78 × 10−7)have been described 
previously to be associated with ALS.14 In addition, we identified 22 additional novel risk 
SNPs, including rs538622 (nearest gene, ERGIC1 [GenBank 57222]; FDR for ALS and 
FTD, P = 3.07 × 10−2; ALS P = 1.37 × 10−5; eTable 2 in the Supplement). Among these 
novel risk SNPs, we identified rs7224296 (nearest gene, NSF), which is located on 
chromosome 17 and occurs within the 1-megabase (Mb) inversion of the MAPT (GenBank 
4137) haplotype.
eQTL and sQTL
To begin to define the functional effects of these shared risk SNPs, we evaluated cis-eQTL in 
human brains free of neuropathologic characteristics (Table 2). The SNP rs7224296 near 
NSF has been previously reported to tag the MAPT H1 haplotype.9 The MAPT H1 
haplotype is associated with increased risk for FTD, PSP, CBD, AD, and PD.10,11,13,16–18 
However, the most significant cis-eQTL with 24296 occurred with KIAA1267 (GenBank 
284058) (also known as KANSL1) (Table 2). rs7224296 is in high LD with rs199533 (D′ = 
−0.97), which was previously reported to be associated with shared risk for PSP, CBD, and 
FTD.9 Consistent with previous findings for rs199533,9 rs7224296 is significantly 
associated with the altered expression of exon 3 within the MAPT gene (Table 2). MAPT H1 
is associated with decreased expression of messenger RNA transcripts containing exons 2 
and 3, which results in the 2N tau protein.32 Together, these findings point to an association 
between the MAPT H1 haplotype and the risk for ALS.
We also identified 2 SNPs sharing genetic overlap between ALS and FTD or ALS and FTD 
with TDP-43 inclusions near C9orf72: rs13302855 and rs3849942 (Table 1). These SNPs 
are not in LD (r2 < 0.02). The SNP rs13302855 produced distinct eQTL with LRRC19 
(GenBank 64922), and rs3849942 produced distinct eQTL with MOBKL2B (GenBank 
79817) (Table 2). Thus, our findings suggest that there are 2 independent signals within the 
C9orf72 locus that confer risk. In addition to cis-eQTL, we examined the association of 
shared risk SNPs with sQTL. We found that rs2282241 (nearest gene, C9orf72; conditional 
FDR ALS and FTD with TDP-43 inclusions, P = 3.68 × 10−5; ALS P = 1.55 × 10−7) was 
significantly associated with alternative splicing of the C9orf72 gene (alternative splicing 
ID, HsaINT0025532; FDR P = 1.08 × 10−3), specifically intron retention. The sQTL SNP 
rs2282241 is in high LD with rs3849942 (D′ = 0.99; Table 1).
Among the novel ALS risk SNPs identified by conditional FDR analysis, we identified cis-
eQTL in human brains (eTable 3 in the Supplement). Most ALS risk SNPs produced cis-
eQTL with genes within the associated locus but not with the nearest named gene. We found 
that rs538622, which is associated with ALS and FTD and falls near the ERGIC1 gene, is 
significantly associated with BNIP1 (GenBank 662) such that the minor allele (G) is 
associated with the lower expression of BNIP1 in human brains (P = 1.1 × 10−3).
Attenuation of Genetic Enrichment After Removing C9orf72 and MAPT
We identified several SNPs in C9orf72 (on chromosome 9)and in LD with MAPT (on 
chromosome 17), suggesting that variants associated with C9orf72 and MAPT were critical 
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in driving our enrichment results. To test this hypothesis, we repeated our enrichment 
analysis after removing all SNPs in LD with r2 > 0.2 within 1 Mb of C9orf72 and MAPT 
variants (based on 1000 Genomes Project33 LD structure). After removing C9orf72 and 
MAPT SNPs, we observed considerable attenuation of genetic enrichment in ALS as a 
function of FTD with TDP-43 inclusions (eFigure 2 in the Supplement). However, we still 
found robust enrichment between ALS and PSP (100-fold enrichment) and sporadic FTD 
(800-fold enrichment; eFigure 2 in the Supplement), suggesting that the observed overlap 
between ALS and FTD was not driven by the C9orf72 and MAPT regions.
Shared Genetic Risk Genes Reveal Dysregulation of Neuronal Networks
To determine whether the shared risk genes fall within common biological pathways, we 
used bioinformatics approaches to identify common pathways. Because most risk SNPs 
occur within intergenic regions, we used 2 approaches to associate a risk SNP with a gene: 
genes nearest the SNPs and genes producing eQTL with the SNPs. Pathway analysis reveals 
that shared risk genes, from conjunction and conditional analyses, fall within pathways 
directly involved in neuronal function: axon guidance, myelin sheath, synaptic vesicle 
pathways, neuronal action potential, and regulation of post-synaptic membrane potential, 
among others (Table 3; eTables 4 and 5 in the Supplement).
Differential Expression of Shared Risk Genes in Tissues of Patients With ALS, FTD, PSP, 
AD, or PD
We next sought to determine whether the risk genes shared across ALS, FTD, PSP, and CBD 
were differentially expressed in disease tissues. To make this determination, we assessed the 
differential expression of the genes nearest the top SNP from conditional and conjunction 
FDR analyses and of the genes that produced the strongest eQTL in our functional analyses 
in motor neurons isolated from spinal cords of patients with ALS and controls (genes 
included in the analysis were taken from Tables 1 and 2 and from eTables 2 and 3 in the 
Supplement).25 Only 15 genes fitting these criteria were present in the ALS data set: BNIP1, 
C20orf24 (GenBank 55969), CAT (GenBank 847), CD59 (GenBank 966), ELL (GenBank 
8178), GPX3 (GenBank 2878), HTRA2 (GenBank 27429), MOBP, MAPT, NFASC 
(GenBank 114), NSF, SCN5A (GenBank 6331), TEK (GenBank 7010), TNFAIP1 
(GenBank 7126), and TNIP1 (GenBank 10318). We found that BNIP1 was significantly 
lower in motor neurons isolated from patients with ALS compared with controls (Figure 2A; 
eTable 6 in the Supplement). MAPT and MOBP were not differentially expressed in the 
motor neurons in patients with ALS and controls (eTable 6 in the Supplement).
Given the genetic overlap, we next examined BNIP1 expression in the brains of patients with 
FTD and PSP. Compared with controls, the BNIP1 expression was significantly reduced in 
the brains of patients with a neuropathologic diagnosis of FTD and PSP (Figure 2B and C). 
MAPT expression was not significantly altered in the brains of patients with FTD or PSP 
relative to controls (eTable 6 in the Supplement).
To further assess whether BNIP1 expression is associated with ALS pathologic 
characteristics, we examined BNIP1 expression in the spinal cords from a transgenic mouse 
model of ALS.26,27 BNIP1 expression was significantly reduced in the spinal cord of SOD1 
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G93A mice compared with SOD1 WT mice (Figure 2G). Thus, BNIP1 expression is 
associated with ALS pathologic characteristics.
Discussion
Using summary statistics from large GWASs (124 876 individuals) and established genetic 
methods, we investigated the genetic overlap between ALS, FTD (sporadic FTD and FTD 
with TDP-43 inclusions), PD, AD, CBD, and PSP. At a conjunction FDR of P < .05, we 
identified up to 300-fold enrichment in genetic risk for ALS across different levels of 
significance for FTD and PSP. Conjunction FDR analyses revealed shared loci previously 
associated with ALS risk as well as several loci not previously implicated in disease risk but 
that point to genetic drivers of neuronal function and mitophagy. Using this approach, we 
report novel genetic overlap between ALS and diseases of the FTD spectrum within the 
MAPT H1 haplotype.
We observed multiple signals within chromosome 9 that were associated with risk between 
ALS and FTD (the cohort defined by TDP-43 pathologic characteristics) and ALS and PSP. 
Among these, rs3849942 is associated with C9orf72 repeat expansions that cause ALS and 
is used as a surrogate marker for the C9orf72 expansion haplotype.34–36 Consistent with 
these reports, our sQTL findings suggest that SNPs in LD with rs3849942 modify C9orf72 
splicing. Thus, it is likely that C9orf72 expansion carriers are present in multiple data sets 
and are driving some of the association. However, given that rs3849942 is not in LD with a 
second SNP near C9orf72, 3O2855, we may be detecting an independent signal on 
chromosome 9 that is associated with the risk for ALS, FTD, and PSP.
Mutations in MAPT cause autosomal dominant forms of FTD.37 Among FTD, PSP, and 
CBD, common variants in MAPT that tag the H1 haplotype represent the strongest genetic 
predictor of disease.10,11,13,16–18 In addition, the MAPT H1 haplotype has been associated 
with PD and AD.10,11,13,16–18 The MAPT H1 haplotype has recently been implicated in 
ALS risk in a meta-analysis of publications on neurodegenerative disease.38 The risk SNP 
tagging the MAPT H1 haplotype, rs7224296, is associated with altered splicing of MAPT of 
exon 3, which, together with exon 2, encodes 2N-containing transcripts. Although the role 
that individual MAPT transcripts play in normal physiology and disease remains poorly 
understood, a recent study of human-induced pluripotent stem cell-derived neurons from 
MAPT haplotype carriers suggests that the H1 haplotype influences axonal transport 
velocities.39 In ALS, these potential gene-induced deficits in axonal transport could alter 
disease onset and/or progression.
Conditional FDR analyses offer the opportunity to begin to reveal novel ALS risk loci. 
Using this approach, we identified 29 SNPs at a conditional FDR of P < .05. Within 
chromosome 5, we identified a risk locus at rs538622 (nearest gene, ERGIC1) that produced 
a significant eQTL in human brains with BNIP1. BNIP1 is a proapoptotic protein (Bcl-2 
family member) involved in the regulation of endoplasmic reticulum structure and 
mitophagy.40,41 BNIP1 is highly expressed in neurons (eFigure 3 in the Supplement). More 
important, we demonstrate that BNIP1 is significantly lower in central nervous system 
tissues from patients with ALS, FTD, and PSP. Because neuronal cell loss is a hallmark 
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feature of neurodegenerative disease and because BNIP1 is a neuronally expressed gene, we 
find that BNIP1 is specifically reduced in both motor neurons isolated from the spinal cords 
of patients with ALS compared with the motor neurons from matched controls. BNIP1 plays 
a critical role in mitophagy, a homeostatic mechanism for the selective degradation of 
damaged mitochondria.42 Depletion of BNIP1 in a cell model results in the disintegration of 
the endoplasmic reticulum network.41 Given that endoplasmic reticulum stress and 
mitochondrial dysfunction have been implicated in ALS at the genetic, molecular, and 
cellular levels,43 BNIP1 may represent an important driver of pathologic characteristics.
44–46
 Altered endoplasmic reticulum stress and mitochondrial dysfunction have been 
implicated in PSP and FTD.47–52 The MAPT H1 haplotype has been shown to alter the 
axonal transport velocities of mitochondria, providing a biological connection to 2 of our 
most interesting genetic signals.39
Functionally, beyond mitophagy, we observed enrichment in shared risk genes occurring in 
pathways involved in neuronal health and maintenance. This finding, taken together with the 
relative lack of enrichment of genes in ALS, AD, and PD, points to the important role that 
genes involved in neuronal heath and function play in driving ALS, FTD, and PSP. Together, 
this study provides genetic, molecular, and functional insights into the effects of risk variants 
shared across the ALS-FTD spectrum.
Limitations
Beyond BNIP1, by leveraging statistical power from large neurodegenerative GWASs, we 
identified numerous novel ALS genetic variants. Although these SNPs warrant replication in 
an independent cohort, our findings suggest that sporadic ALS may represent a polygenic 
disorder characterized by numerous genetic variants, each of which has a small association 
with disease risk. Although no single common variant may be informative clinically, the 
additive combination of risk variants may help identify individuals who are at greatest 
genetic risk for ALS. The GWASs used in these analyses were performed for participants of 
European decent; thus, our findings of the genetic architecture of ALS and FTD spectrum 
disorders may be biased for individuals of European decent. Future studies conducted in 
large non-European populations will be critical for gaining a more complete understanding 
of the genetic architecture underlying ALS and FTD spectrum disorders.
Conclusions
By integrating GWAS data with gene expression data from neurodegenerative disease and 
transgenic mouse models, our multimodal findings implicate the MAPT H1 haplotype in 
ALS and BNIP1 in the ALS-FTD spectrum. Additional work will be required to understand 
the role that tau plays in ALS and the relationship between BNIP1, mitophagy, and 
neurodegenerative diseases.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Key Points
Question
Are there genome-wide genetic risk factors for amyotrophic lateral sclerosis that are 
shared with other neurodegenerative diseases?
Findings
This study of combined genome-wide association data identified selective genetic overlap 
between amyotrophic lateral sclerosis and neurodegenerative diseases within the 
frontotemporal dementia spectrum.
Meaning
These findings identify common genetic pathways between amyotrophic lateral sclerosis 
and frontotemporal dementia and suggest that MAPT and BNIP1 influence the 
pathogenesis of amyotrophic lateral sclerosis.
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Figure 1. Genetic Enrichment Across the Amyotrophic Lateral Sclerosis (ALS)-Frontotemporal 
Dementia (FTD) Spectrum
A, Fold-enrichment plots. Graphs depict enrichment vs nominal -log10 P values (corrected 
for inflation) in amyotrophic lateral sclerosis (ALS) below the standard genome-wide 
association study threshold of P < 5 × 10−8 as a function of significance of association with 
Parkinson disease (PD), Alzheimer disease (AD), corticobasal degeneration (CBD), 
progressive supranuclear palsy (PSP), frontotemporal dementia (FTD) (sporadic and FTD 
with TDP-43 inclusions [TDP43]) and at the level of −log10 P ≥ 0 corresponding to −log10 P 
≤ 1, −log10 P ≥ 1 corresponding to P ≤ .10, and −log10 P ≥ 2 corresponding to P ≤ .01. B, 
Conjunction Manhattan plot showing shared risk loci. A plot of conjunction −log10 (false 
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discovery rate [FDR]) values for ALS given PSP, CBD, TDP-43, and FTD. Single-
nucleotide polymorphisms (SNPs) with conjunction −log10 FDR > 1.3 (ie, FDR P < .05) are 
shown as large points. A black line around the large points indicates the most significant 
SNP in each linkage disequilibrium block. This SNP was annotated with the nearest gene, 
which is listed above the symbols in each locus.
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Figure 2. Reduced BNIP1 Expression in Neurodegenerative Tissue
A, Differential expression in motor neurons isolated from patients with amyotrophic lateral 
sclerosis (ALS) (GSE833 [Gene Expression Omnibus accession number]; mean [SEM] 
value, 3984 [760.8] arbitrary units [AU] for 4 controls and 1999 [274.1] AU for 7 patients 
with ALS; P = .02).
B, Differential expression in homogenates from brains of patients with frontotemporal 
dementia (FTD) (GSE13162; mean [SEM] value, 6.7 [0.05] AU for 11 controls and 6.5 
[0.04] AU for 17 patients with FTD; P = .005). C, Differential expression in homogenates 
from brains of patients with progressive supranuclear palsy (PSP) (syn6090802; mean 
[SEM] value, 6.8 [0.2] AU for 80 controls and 6.8 [0.1] AU for 84 patients with PSP; P = .
009). D, Differential expression in homogenates from spinal cords of SOD1 WT and SOD1 
G93A transgenic mice (GSE4390; mean [SEM] value, 13.8 [0.09]AU for 2 SOD1 WT mice 
and 11.5 [0.025] AU for 2 SOD1 G93A mice; P = .002).
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Table 2
eQTL That Reveal Functional Effects of Shared Risk SNPs in a Human Brain Tissue (UK Brain Expression 
Consortium)
SNP Chr Nearest Gene
eQTL
P Value Gene
rs9820623 3 MOBP 4.40 × 10−3 SCN11A
rs13302855 9 C9orf72 1.30 × 10−2 LRRC19
rs3849942 9 C9orf72 4.80 × 10−3 MOBKL2B
rs7224296 17 NSF 3.30 × 10−18 KIAA1267
6.5 × 10−5 MAPT
6.9 × 10−11 MAPT exon 3
rs4239633 19 UNC13A 1.00 × 10−3 ELL
Abbreviations: Chr, chromosome; eQTL, cis-expression quantitative trait loci; SNP, single-nucleotide polymorphism.
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Table 3
Gene-Based Analysis of Shared Risk Genesa
GOID GO Term FDR
GO:0017075 Syntaxin-1 binding 2.59 × 10−6
GO:0000149 SNARE binding 2.78 × 10−4
GO:0048278 Vesicle docking 3.35 × 10−4
GO:0034706 Sodium channel complex 1.46 × 10−3
GO:0051648 Vesicle localization 2.17 × 10−3
GO:0043209 Myelin sheath 2.28 × 10−3
GO:0006887 Exocytosis 3.22 × 10−3
GO:0016050 Vesicle organization 3.22 × 10−3
GO:0051046 Regulation of secretion 3.90 × 10−3
GO:0001518 Voltage-gated sodium channel complex 4.07 × 10−3
GO:0015629 Actin cytoskeleton 5.45 × 10−3
GO:0014854 Response to inactivity 5.65 × 10−3
GO:0016684 Oxidoreductase activity 6.76 × 10−3
GO:0019226 Transmission of nerve impulse 9.05 × 10−3
GO:0051656 Establishment of organelle localization 0.01
GO:0051640 Organelle localization 0.01
GO:0004601 Peroxidase activity 0.01
GO:0043169 Cation binding 0.01
GO:0043198 Dendritic shaft 0.01
GO:1903561 Extracellular vesicle 0.02
GO:0005911 Cell-cell junction 0.02
GO:0030055 Cell-substrate junction 0.02
GO:0042744 Hydrogen peroxide catabolic process 0.02
GO:0043005 Neuron projection 0.02
GO:0046872 Metal ion binding 0.02
GO:0050678 Regulation of epithelial cell proliferation 0.03
GO:0048705 Skeletal system morphogenesis 0.03
GO:0070161 Anchoring junction 0.03
GO:0005925 Focal adhesion 0.03
GO:0051174 Regulation of phosphorus metabolic process 0.03
GO:0042743 Hydrogen peroxide metabolic process 0.04
GO:0086010 Membrane depolarization during action potential 0.04
GO:0019228 Neuronal action potential 0.04
GO:0030424 Axon 0.05
Abbreviations: FDR, false discovery rate, GO, Gene Ontology; GOID, Gene Ontology Identifier; SNARE, soluble N-ethylmaleimide sensitive 
fusion attachment protein receptor.
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aShared risk genes include genes nearest the single-nucleotide polymorphism and genes producing a cis-expression quantitative trait loci with the 
single-nucleotide polymorphism in conjunction and conditional FDR analyses.
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